28.27
-8.78 (-23.70%)
| Penutupan Terdahulu | 37.05 |
| Jumlah Dagangan | 3,438,845 |
| Harga / Jualan (P/S) | 4.43 |
| Harga / Buku (P/B) | 115.92 |
| Julat 52 Minggu |
| Margin Operasi (TTM) | -2,921.38% |
| EPS Cair (TTM) | -0.640 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -75.50% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 108.28% |
| Nisbah Semasa (MRQ) | 1.03 |
| Aliran Tunai Operasi (OCF TTM) | -34.72 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -18.34 M |
| Pulangan Atas Aset (ROA TTM) | -67.62% |
| Pulangan Atas Ekuiti (ROE TTM) | -221.66% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Cue Biopharma, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 4.0 |
| Purata | 0.21 |
|
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 0.35% |
| % Dimiliki oleh Institusi | 19.45% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Tetragon Partners Gp Ltd | 30 Jun 2026 | 93,819 |
| Stempoint Capital Lp | 30 Jun 2026 | 66,995 |
| Lion Point Capital, Lp | 30 Jun 2026 | 52,928 |
| Squadron Capital Management Llc | 30 Jun 2026 | 50,000 |
| Boothbay Fund Management, Llc | 30 Jun 2026 | 31,459 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |